DONG-A ST
Dong-A ST is a pharmaceutical company specialized in specialty medicines, overseas business, medical devices and diagnostic business.
Dong-A ST possesses four self-developed new drugs, the largest number of domestic pharmaceutical companies, based on its global level of R&D competitiveness.
Zydena, the first erectile dysfunction treatment in Korea, and Sivextro, a superbacterial antibiotic sold in global markets such as the U.S. and Europe,in addition to sugaron, a DPP-4 inhibitor, which is the most preferred in diabetes treatments. It has been recognized for its excellent R&D technology by successfully developing Motiritone, Stillen
Dong-A ST possesses four self-developed new drugs, the largest number of domestic pharmaceutical companies, based on its global level of R&D competitiveness.
Zydena, the first erectile dysfunction treatment in Korea, and Sivextro, a superbacterial antibiotic sold in global markets such as the U.S. and Europe,in addition to sugaron, a DPP-4 inhibitor, which is the most preferred in diabetes treatments. It has been recognized for its excellent R&D technology by successfully developing Motiritone, Stillen